SCHEDULE: Vanguard Trims Coya Therapeutics Stake Below 5%

The Vanguard Group has filed an amended Schedule 13G, disclosing its beneficial ownership in Coya Therapeutics Inc. has fallen to 4.29% following an internal realignment.

Summary

• The Vanguard Group reported beneficial ownership of 899,140 shares of Coya Therapeutics Inc. common stock as of December 31, 2025.
• This represents 4.29% of the class of securities, falling below the 5% threshold.
• Vanguard holds shared voting power over 117,776 shares and shared dispositive power over 899,140 shares.
• An internal realignment occurred on January 12, 2026, where The Vanguard Group, Inc. ceased performing portfolio management services and administering proxy voting.
• Certain subsidiaries or business divisions of Vanguard are expected to report beneficial ownership separately (on a disaggregated basis) in the future.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While Vanguard's stake dropped below 5%, the stated reason is an internal realignment, not a negative assessment of Coya Therapeutics, suggesting the change is administrative rather than performance-driven.

Positives

• Vanguard, a major institutional investor, continues to hold a significant stake in Coya Therapeutics, indicating continued interest, albeit at a reduced level.

Negatives

• The Vanguard Group's beneficial ownership in Coya Therapeutics Inc. has decreased to 4.29%, falling below the 5% threshold, which could be interpreted as a reduction in conviction or a strategic portfolio adjustment.
• The internal realignment at Vanguard means that the consolidated reporting from The Vanguard Group, Inc. will change, potentially making it harder to track the aggregate Vanguard family's holdings in the future without disaggregated reports.

Risks

• The reduction in The Vanguard Group's reported beneficial ownership below 5% could be perceived negatively by the market, potentially impacting investor sentiment.
• The internal realignment within The Vanguard Group, Inc. on January 12, 2026, means that future beneficial ownership reporting will be disaggregated, which could lead to less transparent consolidated reporting from Vanguard as a whole.

Future Outlook

This filing does not provide forward-looking statements or guidance regarding Coya Therapeutics Inc.'s business operations or financial performance.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting.
• The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from major players like Vanguard, are closely watched by the market. While a reduction below 5% might signal a re-evaluation of the position, Vanguard's internal realignment suggests this change is more about internal operational structure and reporting rather than a direct negative assessment of Coya Therapeutics' prospects. This is a common occurrence for large asset managers to streamline operations and reporting.

Comparison to Industry Standards

• This filing does not provide specific performance data for Coya Therapeutics to compare against industry standards.
• The change in Vanguard's ownership is an internal reporting adjustment rather than a direct comparison of Coya's performance to peers like Biogen, Eli Lilly, or Regeneron.

Stakeholder Impact

• Shareholders: The reduction in Vanguard's reported stake might cause some initial concern, but the explanation of an internal realignment could mitigate negative sentiment. Future disaggregated reporting from Vanguard's subsidiaries might make it more complex for individual investors to track the total Vanguard family's exposure.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are expected to report beneficial ownership separately in the future.

Key Dates

Recommendation

The filing indicates a reduction in The Vanguard Group's reported beneficial ownership below the 5% threshold. While this might typically be viewed negatively, the accompanying explanation points to an internal corporate realignment within Vanguard rather than a specific negative outlook on Coya Therapeutics. Given this context, a 'hold' recommendation is appropriate as the change is primarily administrative for Vanguard, and the underlying investment thesis for Coya Therapeutics remains largely unaffected by this specific disclosure. Investors should monitor future disaggregated filings from Vanguard's subsidiaries for a clearer picture of their collective exposure.

Keywords

Coya Therapeutics, Vanguard Group, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake, investment adviser, portfolio realignment